Search Results - "Lublin, FD"

Defining the clinical course of multiple sclerosis : Results of an international survey by LUBLIN, F. D, REINGOLD, S. C

Get full text

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

Effect of relapses on development of residual deficit in multiple sclerosis by LUBLIN, Fred D, BAIER, Monika, CUTTER, Gary

“…To determine the percentage of patients with residual deficits following multiple sclerosis (MS) exacerbations and the magnitude of those deficits using a…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" by Polman, Chris H., Reingold, Stephen C., Edan, Gilles, Filippi, Massimo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred D., Metz, Luanne M., McFarland, Henry F., O'Connor, Paul W., Sandberg-Wollheim, Magnhild, Thompson, Alan J., Weinshenker, Brian G., Wolinsky, Jerry S.

“…New diagnostic criteria for multiple sclerosis integrating magnetic resonance image assessment with clinical and other paraclinical methods were introduced in…”
Get full text

Disease modifying therapies in multiple sclerosis: Report of the therapeutics and technology assessment subcommittee of the American Academy of neurology and the ms council for clinical practice guidelines by GOODIN, D. S, FROHMAN, E. M, GARMANY, G. P, HALPER, J, LIKOSKY, W. H, LUBLIN, F. D, SILBERBERG, D. H, STUART, W. H, VAN DEN NOORT, S

Get full text

Clinical features and diagnosis of multiple sclerosis by Lublin, Fred D

Get more information

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks by Morrow, SA, O'Connor, PW, Polman, CH, Goodman, AD, Kappos, L, Lublin, FD, Rudick, RA, Jurgensen, S, Paes, D, Forrestal, F, Benedict, RHB

“…Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed. Methods: Performance on…”
Get full text

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials by Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R, Agius, M, Arnason, BGW, Bethoux, FA, Bever, CT, Bowen, JD, Brown, TR, Dietrich, DW, Edwards, K, Freedman, MS, Freedman, M, Kachuck, NJ, Kaufman, MD, Keilson, M, Khan, O, Krupp, LB, Leist, TP, Lindsey, JW, Lublin, FD, Mass, MK, Mattson, D, McGowan, D, Naismith, R, O’Connell, C, Oger, JJ, Panitch, H, Picone, MA, Rammohan, KW, Schapiro, RT, Schwid, SR, Scott, T, Short, C, Thrower, BW, Vollmer, TL, Camac, A, Cooper, JA, Chumley, WF, Cross, A, Dunnigan, RT, Gitt, JS, Hillen, M, Jeffrey, DR, Khatri, BO, Kresa-Reahl, K, Moon, S, Preiningerova, J, Tullman, M, Weinstock-Guttman, B, Wynn, DR

“…Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release…”
Get full text

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use by O’Connor, Paul W., Lublin, Fred D., Wolinsky, Jerry S., Confavreux, Christian, Comi, Giancarlo, Freedman, Mark S., Olsson, Tomas P., Miller, Aaron E., Dive-Pouletty, Catherine, Bégo-Le-Bagousse, Gaëlle, Kappos, Ludwig

“…Multiple sclerosis (MS) relapses impose a substantial clinical and economic burden. Teriflunomide is a new oral disease-modifying therapy approved for the…”
Get full text

Mitochondrial DNA mutations in multiple sclerosis by Kalman, B, Lublin, F D, Alder, H

“…The presence of mitochondrial DNA mutations, including eight of those frequently associated with Leber's hereditary optic neuropathy (LHON), was investigated…”
Get more information

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Interferon beta-1b in the treatment of multiple sclerosis : final outcome of the randomized controlled trial

Get full text

Linomide in relapsing and secondary progressive MS. Part I : Trial design and clinical results by NOSEWORTHY, J. H, WOLINSKY, J. S, LUBLIN, F. D, WHITAKER, J. N, LINDE, A, GJORSTRUP, P, SULLIVAN, H. C

Get full text

Therapeutic approaches to secondary progressive multiple sclerosis by Lublin, FD

Get full text

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b : Experience during the first three years

Get full text

Linomide in relapsing and secondary progressive MS. Part II : MRI results by WOLINSKY, J. S, NARAYANA, P. A, NOSEWORTHY, J. H, LUBLIN, F. D, WHITAKER, J. N, LINDE, A, GJÖRSTRUP, P, SULLIVAN, H. C

Get full text

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis by Petkau, A John, White, Richard A, Ebers, George C, Reder, Anthony T, Sibley, William A, Lublin, Fred D, Paty, Donald W

“…We have analysed data on exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody…”
Get full text

When marketing and science intersect: do patients with MS benefit? by Lublin, Fred D

Get full text

Management of patients receiving interferon beta-1b for multiple sclerosis : report of a consensus conference by LUBLIN, F. D, WHITAKER, J. N, EIDELMAN, B. H, MILLER, A. E, ARNASON, B. G. W, BURKS, J. S

“…Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of…”
Get full text